Part of COVID-19 spring 2024 campaign: Cohort identification methodology

Rule logic

Currently GPES data is being pulled from GPES v5

Immunosuppression

Green book description	Data used	Ruleset
Genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID)	GPESv5, HES	All people aged 6 months and over with genetic disorders affecting the immune system, or a chromosomal disorder, or a primary or acquired immune deficiency.
Serious genetic abnormalities that affect a number of systems	GPESv5, HES	Children aged 5 to 15 years with serious genetic abnormalities including those diagnosed with mitochondrial disease and chromosomal abnormalities.
Patients undergoing chemotherapy leading to immunosuppression and patients undergoing radical radiotherapy.	GPESv5, OPCS, SACT, RTDS	Chemotherapy and/or radiotherapy within the last 12 months recorded via SACT (chemotherapy), RTDS (radiotherapy) databases or via GP records. CAR-T treatment recorded in the GP record within the last 24 months.
Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults, and children treated with or likely to be treated with high or moderate dose corticosteroids.	GPESv5	All people aged 6 months and over who have been prescribed four steroid prescriptions on separate days in the last 6 months.
Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.	GPESv5	All people aged 6 months and over receiving immunosuppresive or immunomodulating biological therapies including biological treatment of B cell lymphoma in the last 12 months.
Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.	GPESv5	All people aged 6 months and over who have been prescribed immunsuppressive and non-biological immune modulating drugs including but not limited to methotrexate, azathioprine, hydroxychloroquine, tacrolimus, sulfasalazine, mercaptopurine or mycophenolate.
Solid organ transplant recipients.	GPESv5, HES	All people aged 6 months and over who have received a solid organ transplant.
Human immunodeficiency virus (HIV) infection at all stages, and other specified immunodeficiencies.	GPESv5, HES	All people aged 6 months and over with HIV, acquired autoimmune deficiency (AIDs), and other immunodeficiencies.
People with a history of haematological malignancy including leukaemia, lymphoma and myeloma.	GPESv5, HES, SACT	All people aged 6 months and over with a history of haematological malignancy including leukaemia, lymphoma and myeloma.
Bone marrow or stem cell transplant recipients.	GPESv5, HES, OPCS	All people aged 6 months and over who are bone marrow or stem cell transplant recipients including all people with graft versus host disease

Morbid obesity

Green Book Description	Data used	Rulesets
Adults with a body mass index (BMI) codes >= 40kg/m^2	GPESv5	All people aged 16 years and over with a body mass index greater or equal to 40kg/m^2 recorded in the last 6 months with no subsequent recorded BMI measurement lower than 40.

Severe Mental Illness

Green book description	Data used	Rulesets
Individuals with schizophrenia, bipolar disorder or any mental illness that causes severe functional impairment	GPESv5, HES	All people aged 16 years and over with a diagnosis of schizophrenia, bipolar disorder, or mental illnesses which may lead to severe functional impairment.

Age-based Cohorts

Green book description	Data used	Rule sets
All citizens in England aged 75 years or over	PDS	All people age 75 years or over before 30th June 2024

Last edited: 26 March 2024 11:47 am